Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Smita Mauze"'
Autor:
David Rosen, Laurence Fayadat-Dilman, Yiwei Zhang, Konstantin Dobrenkov, Elliot Chartash, Richard Wnek, Smita Mauze, Hans van Eenennaam, Judith Stammen-Vogelzangs, Ying Yu, Marco Guadagnoli, Lars Guelen, Thierry O Fischmann, Jerelyn Wong, Nikolina Bąbała, Jozef Wagenaars, Veronica Juan, Winnie Prosise, Maurice Habraken, Imke Lodewijks, Danling Gu, Jeanne Baker, David Lutje Hulsik, Lilian Driessen-Engels, Dan Malashock, Joost Kreijtz, Astrid Bertens, Evert de Vries, Astrid Bovens, Arne Bramer, Sean Troth, Svetlana Sadekova, Andrea van Elsas, Jason K Cheung, Jannie Borst, Amy M Beebe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Immune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement ICI therapy. CD27 is a member of
Externí odkaz:
https://doaj.org/article/cc59fd0a12e04837b4168ce751ae8a2b
Autor:
Peng Yang, Wendy Blumenschein, David Bauché, Smita Mauze, Christina Kochel, Jeff Grein, Anandi Sawant, Yulia Zybina, Lakshmanan Annamalai, Jennifer H Yearley, Juha Punnonen, Edward P Bowman, Alissa Chackerian, Drake Laface
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Programmed cell death protein 1 (PD-1) and CTLA4 combination blockade enhances clinical efficacy in melanoma compared with targeting either checkpoint alone; however, clinical response improvement is coupled with increased risk of developi
Externí odkaz:
https://doaj.org/article/1bda0443d10a44cca19b501ab433abcf
Autor:
Renu Jain, Daniel J. Cua, Amy M. Beebe, Edward P. Bowman, Jane Xia, Barbara Joyce-Shaikh, Smita Mauze, Ashley E. Mahne
Agonistic monoclonal antibodies (mAb) targeting the T-cell receptor coregulatory molecule GITR exert potent therapeutic activities in preclinical tumor models. Although anti-GITR mAb are thought to act by depleting and destabilizing the intratumoral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::981bd21ef7d17b20d8714f271ff1f6c8
https://doi.org/10.1158/0008-5472.c.6509418.v1
https://doi.org/10.1158/0008-5472.c.6509418.v1
Autor:
Renu Jain, Daniel J. Cua, Amy M. Beebe, Edward P. Bowman, Jane Xia, Barbara Joyce-Shaikh, Smita Mauze, Ashley E. Mahne
Supplementary Materials and Methods include Treg lineage tracing data in B16 melanoma tumor model and binding, pharmacokinetics characterization and agonist signaling activity data for mDTA-1 Fc mutant antibody.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ac176463991410d7d89b3b66898ce5f
https://doi.org/10.1158/0008-5472.22415922.v1
https://doi.org/10.1158/0008-5472.22415922.v1
Autor:
Lars Guelen, Thierry O Fischmann, Jerelyn Wong, Smita Mauze, Marco Guadagnoli, Nikolina Bąbała, Jozef Wagenaars, Veronica Juan, David Rosen, Winnie Prosise, Maurice Habraken, Imke Lodewijks, Danling Gu, Judith Stammen-Vogelzangs, Ying Yu, Jeanne Baker, David Lutje Hulsik, Lilian Driessen-Engels, Dan Malashock, Joost Kreijtz, Astrid Bertens, Evert de Vries, Astrid Bovens, Arne Bramer, Yiwei Zhang, Richard Wnek, Sean Troth, Elliot Chartash, Konstantin Dobrenkov, Svetlana Sadekova, Andrea van Elsas, Jason K Cheung, Laurence Fayadat-Dilman, Jannie Borst, Amy M Beebe, Hans Van Eenennaam
Publikováno v:
Journal for ImmunoTherapy of Cancer, 10(9). BMJ PUBLISHING GROUP
BackgroundImmune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement ICI therapy. CD27 is a member of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92e2a5657834d447f836b811d356fb97
https://doi.org/10.1136/jitc-2022-005049
https://doi.org/10.1136/jitc-2022-005049
Autor:
Juha Punnonen, Lakshmanan Annamalai, Edward P. Bowman, Peng Yang, Drake LaFace, Jennifer H. Yearley, Anandi Sawant, Alissa A. Chackerian, Smita Mauze, Jeff Grein, Wendy M. Blumenschein, David Bauché, Yulia Zybina, Christina Kochel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundProgrammed cell death protein 1 (PD-1) and CTLA4 combination blockade enhances clinical efficacy in melanoma compared with targeting either checkpoint alone; however, clinical response improvement is coupled with increased risk of developin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b844e8ae21e846e989431cbcfc0e697
https://jitc.bmj.com/content/8/2/e001584.full
https://jitc.bmj.com/content/8/2/e001584.full
CD4+ T cells in the mouse can be subdivided into two fractions based on the level of expression of the CD45RB determinant. Previous studies have shown that these subsets are functionally distinct. We have further characterized the properties of these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0a13cdc22d6daf9782a003fbf65ee8
https://doi.org/10.1093/intimm/5.11.1461
https://doi.org/10.1093/intimm/5.11.1461
Publikováno v:
The Journal of Experimental Medicine
BALB/c mice infected with the intracellular protozoan Leishmania major mount a T helper cell 2 (Th2) response that fails to control growth of the parasite and results in the development of visceral leishmaniasis. Separation of CD4+ T cells into CD45R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::454f29a5858db77e918cafb47d9253cf
https://doi.org/10.1084/jem.179.2.589
https://doi.org/10.1084/jem.179.2.589
Autor:
Gulesi Ayanoglu, Erin Murphy, Scott P. Turner, Amy M Beebe, Ivan H. Chan, John B. Mumm, Venkataraman Sriram, Xueqing Zhang, Catherine Sheppard, Jeff Grein, Beth Basham, Martin Oft, Satya Medicherla, Jan Emmerich, Melanie A. Kleinschek, Lingling Wu, Michael Judo, Steven J. Blaisdell, Terrill K. McClanahan, Susan Cannon-Carlson, John L. Langowski, Danling Gu, Kyu Hong, Wolfgang Seghezzi, Smita Mauze, Brittany C. Paporello, Bela Desai, Saraswathi Naravula, Jie Dai, Drake LaFace, Collette M. Cutler
Publikováno v:
Cancer Cell. 20(6):781-796
Summary Tumor immune surveillance and cancer immunotherapies are thought to depend on the intratumoral infiltration of activated CD8 + T cells. Intratumoral CD8 + T cells are rare and lack activity. IL-10 is thought to contribute to the underlying im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be7a3a8453fea6fe1ae6913680436ca
Autor:
Shuli Zhang, Amy M Beebe, Douglas Hodges, Roanna Ueda, Derek Wiswell, Nicholas D. Brunn, Enrique Escandón, Smita Mauze, Danling Gu
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 356(3)
Administration of biologics to enhance T-cell function is part of a rapidly growing field of cancer immunotherapy demonstrated by the unprecedented clinical success of several immunoregulatory receptor targeting antibodies. While these biologic agent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c56d35be73132c9db7d3e7bc7f1fdb7f
https://pubmed.ncbi.nlm.nih.gov/26669426
https://pubmed.ncbi.nlm.nih.gov/26669426